Advertisement
Singapore markets closed
  • Straits Times Index

    3,297.55
    -26.98 (-0.81%)
     
  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     
  • Dow

    38,589.16
    -57.94 (-0.15%)
     
  • Nasdaq

    17,688.88
    +21.28 (+0.12%)
     
  • Bitcoin USD

    66,563.95
    +418.11 (+0.63%)
     
  • CMC Crypto 200

    1,383.04
    -34.83 (-2.46%)
     
  • FTSE 100

    8,146.86
    -16.81 (-0.21%)
     
  • Gold

    2,340.30
    -8.80 (-0.37%)
     
  • Crude Oil

    78.17
    -0.28 (-0.36%)
     
  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     
  • Nikkei

    38,067.87
    -746.69 (-1.92%)
     
  • Hang Seng

    17,941.78
    0.00 (0.00%)
     
  • FTSE Bursa Malaysia

    1,607.32
    -2.85 (-0.18%)
     
  • Jakarta Composite Index

    6,734.83
    -96.73 (-1.42%)
     
  • PSE Index

    6,383.70
    -7.13 (-0.11%)
     

Better Long-Term Buy: AbbVie or Novo Nordisk?

Better Long-Term Buy: AbbVie or Novo Nordisk?

Pharmaceutical companies Novo Nordisk (NYSE: NVO) and AbbVie (NYSE: ABBV) seem to be headed in separate directions. Denmark-based Novo Nordisk, thanks to growing sales of diabetes drug Ozempic and obesity therapy Wegovy, is predicting sales to grow between 24% to 30% and operating profit to rise 28% to 34% this year. AbbVie, on the other hand, thanks to the loss of patent protection for immunology blockbuster Humira, has forecasted 2023 adjusted earnings per share (EPS) to drop by 20% to 23%, from 2022 levels.